Update on COVID-19 in WHO ’s Eastern Mediterranean Region
9 June 2021 – As of 08 June 2021 (11:59 PM), the Eastern Mediterranean Region has reported 10 353 336 confirmed COVID-19 cases and 206 573 deaths. While the total number of cases has declined over the past 6 weeks and the number of deaths stabilized, 9 countries reported an increase in cases last week, compared to the previous week. These include Somalia, Sudan and Afghanistan, who reported the highest increase in cases. Eleven countries reported an increase in deaths last week, with the highest numbers reported from Sudan, Afghanistan and Morocco. Variants of concern (VOC) continue to circulate across the Region. To date, 17 countries have officially reported the detection of the VOC Alpha, 10 countries have reported the VOC Beta, 3 countries have officially reported the detection of the VOC Gamma, and 6 countries have reported the VOC Delta (B.1.617.2). In countries where cases of COVID-19 are increasing, we currently have no data to support that this increase is a result of new variants. We are carefully monitoring the situation and encouraging all countries to conduct genomic sequencing analysis so that we can identify new variants and monitor their changes over time. 14 countries in the Region now have local capacity to conduct genomic sequencing in order to detect SARS CoV-2 variants of concern. The other 8 countries receive WHO support to sequence abroad. Two regional reference laboratories are currently supporting other countries in genomic s...
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
Publication date: Available online 10 October 2020Source: Journal of Hospital InfectionAuthor(s): Hisakazu Yano, Ryuichi Nakano, Yuki Suzuki, Akiyo Nakano, Kei Kasahara, Hiroshi Hosoi
Authors: Yepes-Pérez AF, Herrera-Calderon O, Sánchez-Aparicio JE, Tiessler-Sala L, Maréchal JD, Cardona-G W Abstract COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2. Presently, there is no effective treatment for COVID-19. As part of the worldwide efforts to find efficient therapies and preventions, it has been reported the crystalline structure of the SARS-CoV-2 main protease Mpro (also called 3CLpro) bound to a synthetic inhibitor, which represents a major druggable target. The druggability of Mpro could be used for discovering drugs to treat COVID-19. A multil...
Conclusions: Early results of universal preoperative screening for COVID-19 demonstrates a low incidence and high rate of asymptomatic patients. Health care professionals, especially those at higher risk for the virus, should be aware of the challenges related to screening based solely on symptoms or travel history and consider universal screening for patients undergoing elective surgery. Level of Evidence: Level II.
The case offers proof that "SARS-CoV-2 can also infect ocular tissues in addition to the respiratory system," the doctors reported in the Oct. 8 online edition of the journal JAMA Ophthalmology.
Publication date: Available online 9 October 2020Source: Journal of Hospital InfectionAuthor(s): Makoto Hibino, Shogo Iwabuchi, Hiromi Munakata
To investigate the relationship between maximal exercise capacity measured before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and hospitalization due to coronavirus disease 2019 (COVID-19).
We present the case of a very rapid neurologic and radiographic decline of a patient with an acute ischemic stroke who developed rapid fulminant cerebral edema leading to herniation in the setting of hypercarbic respiratory failure attributed to SARS-CoV-2 infection.
After being epidemic in China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) infection has rapidly spread in many countries as a global pandemic, with the number of affected cases dramatically increasing worldwide on a daily basis. Although the median age of hospitalized patients with confirmed infection is usually more advanced 1, with older age reported to be associated to higher mortality rate 2, physiological adaptations occurring during pregnancy have been claimed to be potentially responsible for a more severe respiratory disease, thus leading to higher rates of maternal and fetal complications 3,4.